Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Recruitment Status: Recruiting"
topic_facet:"Lung Neoplasms"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Recruiting%22&filter%5B%5D=topic_facet%3A%22Lung+Neoplasms%22&lookfor=%22Study+Type%3A+Interventional%22&type=Subject
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Recruiting%22&filter%5B%5D=topic_facet%3A%22Lung+Neoplasms%22&lookfor=%22Study+Type%3A+Interventional%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Recruiting%22&filter%5B%5D=topic_facet%3A%22Lung+Neoplasms%22&lookfor=%22Study+Type%3A+Interventional%22&type=Subject
PubPharm (1.227)
1
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) : Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
2
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial : Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
3
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer : A Phase 1 Open-Label Study of HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
4
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) : A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
5
Evaluation of the Synergistic Impact of Needle and Forceps Biopsy With Electromagnetic Navigation Bronchoscopy : Comparison and Synergistic Evaluation of Needle Aspiration and Forceps Biopsy for Diagnosis of Lung Lesions With Electromagnetic Navigation Bronchoscopy
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
6
Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer : The Potential Risks and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
7
Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer : Utilizing Patient Reported Quality of Life to Inform Patient Decision Making in Early-Stage Lung Cancer
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
8
Safety and Efficacy of Intravenous Cemiplimab Plus BNT116 Versus Cemiplimab Alone in Advanced Non-Small Cell Lung Cancer in Adult Participants With PD-L1 ≥ 50% : A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
9
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer : Administration of T Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch in Subjects With Lung Cancer
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
10
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer : Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[123]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Recruitment Status: Recruiting
Filter aufheben
Thema: Lung Neoplasms
Medienart
1.227
Aufsätze
1.227
E-Artikel
1.227
E-Ressourcen
Zeitschriftentitel
1.227
ClinicalTrials.gov
Thema
1.227
610
Lung Neoplasms
Recruitment Status: Recruiting
1.227
Study Type: Interventional
701
Carcinoma, Non-Small-Cell Lung
394
Phase: Phase 2
170
Small Cell Lung Carcinoma
165
Phase: Phase 1
158
Phase: Phase 3
138
Phase: Phase 1, Phase 2
115
Carcinoma
70
Neoplasms
45
Neoplasm Metastasis
36
Brain Neoplasms
30
Medical Condition: Non-small Cell Lung Cancer
28
Colorectal Neoplasms
28
Medical Condition: Non Small Cell Lung Cancer
27
Medical Condition: Lung Cancer
24
Phase: Early Phase 1
20
Melanoma
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
1.167
2020-
60
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
1.227
Englisch
Haven't found what you're looking for?
Wird geladen...